butyl-(5-methyl-1H-[1,2,4]triazol-3-yl)-amine | 62400-53-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: butyl-(5-methyl-1H-[1,2,4]triazol-3-yl)-amine
• 英文别名: N-Butyl-5-methyl-1H-1,2,4-triazol-3-amine；N-butyl-5-methyl-1H-1,2,4-triazol-3-amine
• CAS: 62400-53-7
• 化学式: C₇H₁₄N₄
• 分子量: 154.215
• InChiKey: HZEVVQZJJKRLRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  53.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：ELCELYX THERAPEUTICS INC

  公开号：WO2013103919A2

  公开（公告）日：2013-07-11

  Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.
• [EN] COMPOSITIONS COMPRISING STATINS, BIGUANIDES AND FURTHER AGENTS FOR REDUCING CARDIOMETABOLIC RISK<br/>[FR] COMPOSITIONS COMPORTANT DES STATINES, DES BIGUANIDES ET D'AUTRES AGENTS POUR RÉDUIRE UN RISQUE CARDIOMÉTABOLIQUE
  申请人：ELCELYX THERAPEUTICS INC

  公开号：WO2014011926A1

  公开（公告）日：2014-01-16

  Compositions and methods comprising at least one biguanide compound and at least one statin combined with at least one additional active agent in fixed dose combinations are provided for reducing cardiometabolic risk, and for the treatment of cardiovascular disease, wherein the biguanide compound is formulated for delayed release.
• [EN] DELAYED-RELEASE COMPOSITION COMPRISING BIGUANIDE<br/>[FR] COMPOSITIONS ET MÉTHODES PERMETTANT DE TRAITER DES AFFECTIONS MÉTABOLIQUES
  申请人：ELCELYX THERAPEUTICS INC

  公开号：WO2014107617A1

  公开（公告）日：2014-07-10

  Compositions and methods for improving the pharmacokinetics and reducing the risk of adverse events resulting from biguanide compound administration are provided, comprising administering delayed release formulations of such compounds having a lag phase release.